Baader Bank Aktiengesellschaft acquired a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 77,053 shares of the medical research company's stock, valued at approximately $4,329,000.
A number of other large investors have also modified their holdings of the company. Huntington National Bank grew its stake in shares of Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after buying an additional 352 shares during the period. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences during the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP acquired a new stake in Exact Sciences during the 3rd quarter worth approximately $35,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences in the 4th quarter valued at $43,000. Finally, Vestor Capital LLC acquired a new stake in shares of Exact Sciences in the 3rd quarter valued at $46,000. Institutional investors and hedge funds own 88.82% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently commented on EXAS shares. Barclays started coverage on shares of Exact Sciences in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $70.00 target price on the stock. BTIG Research raised their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Robert W. Baird reduced their target price on shares of Exact Sciences from $70.00 to $67.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Piper Sandler reduced their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. Finally, Citigroup cut their target price on shares of Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.76.
View Our Latest Stock Report on Exact Sciences
Exact Sciences Trading Up 2.2 %
EXAS traded up $1.19 during trading on Thursday, hitting $56.08. 614,568 shares of the company's stock were exchanged, compared to its average volume of 2,430,906. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The stock has a 50 day moving average price of $57.73 and a 200 day moving average price of $59.71. The firm has a market cap of $10.38 billion, a P/E ratio of -47.87 and a beta of 1.24.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The firm had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Exact Sciences's quarterly revenue was up 12.8% compared to the same quarter last year. As a group, analysts expect that Exact Sciences Co. will post -1.1 EPS for the current fiscal year.
Insider Activity at Exact Sciences
In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the stock in a transaction on Wednesday, November 13th. The stock was purchased at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the purchase, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.36% of the stock is currently owned by corporate insiders.
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
